Ligand Pharma (LGND) Tops Q3 EPS by 5c; Guides Q4, FY14

Ligand Pharma (NASDAQ: LGND) reported Q3 EPS of $0.36, $0.05 better than the analyst estimate of $0.31. Revenue for the quarter came in at $15 million versus the consensus estimate of $14.6 million.

Ligand Pharma sees FY2014 EPS of $1.50-$1.55, versus the consensus of $1.56. Ligand Pharma sees FY2014 revenue of $64-66 million, versus the consensus of $64.6 million.

Ligand Pharma sees Q4 2014 EPS of $0.57-$0.62, versus the consensus of $0.67. Ligand Pharma sees Q4 2014 revenue of $22.5-24.5 million, versus the consensus of $23.5 million.

For earnings history and earnings-related data on Ligand Pharma (LGND) click here.

You May Also Be Interested In

• EU proposes to curb Airbnb and short-term rentals amid housing shortage
• Asana, Inc. (ASAN) Tops Q2 EPS by 1c; offers guidance
• BlackRock’s Rosenberg says inflation data key after jobs beat